Understanding Stem Cell Transplant 2007
|
|
|
- つねとき さわなか
- 6 years ago
- Views:
Transcription
1 Understanding Stem Cell Transplant IMF International Myeloma Foundation Riverside Drive, Suite 206 North Hollywood, CA USA Telephone: CURE (2873) (USA & Canada) Fax: /07
2 David Vesole Brian Durie 2007, International Myeloma Foundation, North Hollywood, California
3 ? 4 5
4 M 4 M ISS 2 2M 3.5g/dl 2 3.5mg/dl 3.5 g/dl mg/dl g/dl 2 5.5mg/dl M ""
5
6 HLA "" HLA (MUD) (HLA) 100 " " VAD VDD IMF( )
7 36 50 PR 50% VGPR 90% CR ) VGPR CR VGPR CR VAD VGPR CR VGPR CR VGPR CR CR ) VGPR " "[] VGPR CR VGPR CR VGPR PR[] PR50% VGPR90% CR100%
8 PR()VGPR CR 50PR "" ""
9 Neupogen Neulasta Leukine [PBSC] 1) 2) 1) 2)
10 "Tylenol " 2 DMSO 10 CD34+ CD34+ kg 200 CD34+ CD34+ CD34+ 2 kg 400 CD
11 AMD-3100 ("Mozobil ") 200mg (mg/) {} DMSO
12 3 2,
13 4 36 QOL 24 25
14 2 6 2 VGPR CR "Quadramet " Sm-153 "" GVHD 4 GVHD 26 27
15 28 29
16 IMF IMF 30 31
17 , "" QOL
18
19 36 37
20 IMF 1 2 IMF. D. 75, ,000 20,000 IMF IMF 4 IMF 185,000 IMF IMF IMF 38 39
21 IMF IMF InfoPack IMF IMF 24 : CURE (2873) IMF IMF 100 IMF IMF Myeloma Minute BANK ON A CURE DNA ISS Myeloma Matrix IMF IMF Myeloma Today 40 41
22 DNA HLA (NMDP) 13 14g/dl 10g/dl CD34+ CD
23 CSF() "Neupogen" "Neulasta""Leukine" CR: CR CR ISS 20 M M M M M M PBSC "" PBSC PBSC CR CR 44 45
24 VGPR) 100 M Attal M, Harrousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335: Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized trial. Blood. 1998;92: Barlogie B, Jagannath S. Desikan KR< et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93: Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348: Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349: Fassas AB, Van Rhee F, Tricot G. Predicting long-term survival in multiple myeloma patients following autotransplants. Leuk Lymphoma. 2003;44: Blade J. Transplantation for multiple myeloma: who, when, how often? High-dose therapy in multiple myeloma. Blood. 2003;15: Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and menatopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354: Cavo M, Baccarani M. The changing landscape of myeloma therapy. N Engl J Med. 2006;354: Barlogie B, Tricot G. Complete response in myeloma: a Trojan horse? Blood. 2006;108:2134. IMF IMF
10 2 2 10 6.5 78 1 65 / 30 / - 2 -
- 1 - 10 2 2 10 6.5 78 1 65 / 30 / - 2 - 3 3 30 8 4 8 6 11 14 45 14 7 8 1-3 - 4 1 () 20 4 9 4 9 3 9 4 PR 4 3-4 - - 5 - PR 15 4 PR 7 8 4 9 10-6 - 9 10 9 10 4 9 10 3 9 10 9 9 9 10 PR 1-7 - PR - 8 - 30 100-9
051
Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 389( 15 ) 1. MDS collagenase 2. 1 3. 4. / 390( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 Aug. 4 4 2004 10 2 1 NTT Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS
untitled
Shinichiro Okamoto MD, PhD Keio University School of Medicine Tokyo Japan vincristine) Berberidaceae etoposide VP-16) MRD 10 12 PCR 10 10 10 8 10 6 10 4 10 2 ( CR) ( CR) AML Study n Ind Consol % 3
日本内科学会雑誌第105巻第7号
トピックス Ⅵ. 多発性骨髄腫に対する標準治療 多発性骨髄腫に対する標準治療 要旨 多発性骨髄腫 (multiple myeloma:mm) の治療成績は, 新規薬剤の導入により深い奏効が得られるようになったことや, 再発難治例にも有効な治療薬が登場したことにより改善している. 若年者の初回標準治療は, 新規薬剤を組み込んだ寛解導入療法に続く自家移植併用大量化学療法である. この10 年の骨髄腫の治療成績向上は,
食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
C/NC : committed/noncommitted
C/NC : committed/noncommitted 110 time post-icd implant 1) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report : Effect of encainaide and flecainide on mortality in a
取扱説明書 ［F-02F］
F-02F 4. 2 3 4 5 6 7 8 9 0 2 3 4 5 6 7 8 a b c d a b c d a b cd 9 e a b c d e 20 2 22 ab a b 23 a b 24 c d e 25 26 o a b c p q r s t u v w d h i j k l e f g d m n a b c d e f g h i j k l m n x 27 o
取扱説明書 ［F-06E］
F-06E 3.6 2 3 4 5 6 7 8 9 0 2 3 4 5 6 a b c d a b c d 7 a b cd e a b c 8 d e 9 20 a b b a a b 2 22 b a c 23 d 24 a b c d e f g h l m n o p i j k ku v w q r s t x y a b c d e f g h i j k l m n o p q
! 1Munderl P et al. Survival and causes of death, 2 years after Introduction of antiretroviral therapy in Africa. XVI International AIDS Conference, 2006, Abstract THLB0208. 2Walensky RP et al. The
1 2 2 ANCA pouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - ' UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, cm 61
1 2 2 ANCApouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - '03 2 3 31 UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, 3+ 4 14 156.0 cm 61.5 kg 36.9 158/92 mmhg 90 1. ANCA 2. 3. IgG4 deposit
骨髄異形成症候群に対する 同種造血幹細胞移植の現状と課題
第 36 回造血幹細胞移植委員会 (H25.2.4) 資料 5 第 36 回厚生科学審議会疾病対策部会造血幹細胞移植委員会 日本造血細胞移植学会 (JSHCT) 移植医療の現場からの提言 日本造血細胞移植学会理事長 岡本真一郎 我が国における非血縁者間造血幹細胞移植数 2000 1800 1600 1400 1200 1000 800 600 400 200 非血縁者間骨髄移植非血縁者間臍帯血移植
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
M1 TSH T 3 T 4 2 T 1 2 Plummer 3 TSH TSH K 5 7 TSH TSH Plummer TSH TSH TSH TSH T 4 T 3 TSH T 4 T 3 TSH TSH or Plummer Plummer or a) 1. 2. 3. b) 1. T 4 T 3 2. TSH 0.1 U/ml 3. TSH TRAb TSAb 4. 1) a) 1
病態と治療のあらまし
Concise Review of the Disease and Treatment Options Multiple Myeloma Cancer of the Bone Marrow International Myeloma Foundation 2007 GM 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. (1) (2) (3) (4)
取扱説明書 ［F-05E］
F-05E 12.11 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 a b 22 c d e 23 24 a o c d a b p q b o r s e f h i j k l m g f n a b c d e f g h 25 i j k l m n o p q r s a X b SD 26 27 28 X 29 a b c
qxd
BD FACS TM Review Vol.7 BD FACSAria TM BD FACSAria FACS HLA-FACS Key words: HLA FACS 1988 Eliane Glukmann Fanconi 1 5 10% 30% mixed chimerism HLA human leukocyte antigen HLAFACS fluorescence activated
1 2 1 3 2 4 22 NPO PR NPO NPO 22 10 4 2,000kg 1kg 5 2 1 4,000 20,000 26 33 27 24 3 19 24 3 4 3 4 3 () 34 3 4 5 23 3 17 23 20 30 1 1 877g/ 3 24 3 1 1 28 897g/ 33 850g/ 22 23 30 1 1 510g/ 22 23 3 24
3675-433897418-1.pdf
A : : : : : : : : : : PR PR NHK 2 PR PR 3 1954 7 4 5 9 12,000 12 100 2 2 11 4 5 6 7 / PR 8 9 10 11 1952 ( ) 2008 2009 2012 NHK km m m 12 m km km kg kg 13 % 14 15 1959 5 20 8 17100kg 400kg How much? 60
特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書（案）
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
本文.indd
CQ ACC/AHA PECO PatientExposure Comparison OutcomePECO low-density lipoprotein cholesterol LDL C cholesterol cholesterol intensive OR agressive CQ target LDL C PubMed Systematic Reviews Clinical Study
164 SDD & SOD SDD E100 mg 80 mg B500 mg 2 E 2 B 48 /59 81 SDD SOD 10 /63 16 RCT RCT 1992 Gastinne 15 ICU 445 SDD E100 mg 80 mg B 10
163 特 集 SDD & SOD SDD(Selective digestive decontamination),sod(selective oropharynx decontamination), 腸内細菌叢, 耐性菌 Ⅰ はじめに SDD Selective digestive decontamination SOD Selective oropharynx decontamination
1 2 3 4 1 3 4 2 5 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 21 24 25 26 27 28 29 30 31 32 33 34 9 35 36 14 9 14 15 37 38 39 35 1 519 4 NPO 40 41 9 10 4 (9 Or10 ) PR 3 21 21 42 2 10 43 44 15
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
Ł½’¬24flNfix+3mm-‡½‡¹724
571 0.0 31,583 2.0 139,335 8.9 310,727 19.7 1,576,352 100.0 820 0.1 160,247 10.2 38,5012.4 5,7830.4 9,5020.6 41,7592.7 77,8174.9 46,425 2.9 381,410 24.2 1,576,352 100.0 219,332 13.9 132,444 8.4 173,450
untitled
NPO 2006( ) 11 14 ( ) (2006/12/3) 1 50% % - - (CO+H2) ( ) 6 44 1) --- 2) ( CO H2 ) 2 3 3 90 3 3 2 3 2004 ( ) 1 1 4 1 20% 5 ( ) ( ) 2 6 MAWERA ) MAWERA ( ) ( ) 7 6MW -- 175kW 8 ( ) 900 10 2 2 2 9 -- - 10
SBP hospitalist network.key
1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous
16 MHC 2018; 25 (1) 参加費 1 2, , ,000 会議等 :00 13: :00 13: :20 会場地図 TEL JR 350 m 57
Major Histocompatibility Complex 2018; 25 (1): 56 82 抄録集 16 2018 3 3 7 2 4 43 TEL 06 6962 7001 594 1101 840 TEL 0725 56 1220 56 16 MHC 2018; 25 (1) 参加費 1 2,000 2 1,000 3 3,000 会議等 1 3 3 13:00 13:10 2 3
胆石症
,. vs 64 .. vs. -, Ransohoff DF, Gracie W. Treatment of gallstones. Ann Intern Med ; 119 : - Halldestam I, Enell EL, Kullman E, et al. Development of symptoms and complications in individuals with asymptomatic
03慢性骨髄性白血病CML.indd
慢* 59 病CML略語一覧 Ⅰ クリニカルクエスチョン一覧 Ⅱ 略語一覧 慢性骨髄性白血病 CML CQ 1 小児 CML の標準的治療は何か CQ 2 小児 CML 治療における造血幹細胞移植の役割は何か CML (Chronic Myelocytic Leukemia, 慢性骨髄性白血病 ) TKI (Tyrosine Kinase Inhibitor, チロシンキナーゼ阻害薬 ) CHR (Complete
untitled
1. 1 2. 2 3.,1995 3 223119 3.1,, 4 3.2 NTT,2003 5 mile,2003 4.,, 6 , 2001 22 126 7 9 34 22 22 8 (139) 8 6. 6.1,,,,,, 9 6.2a Who What Whom When How Where 3 4 5 4 8 8 4, 7 6,,,, 2 or 3 6.2NGO NGO Who What
....
2030 2 Vol. 22 No. 32000 1/2 EE F FAF 60E 1970 40 25FIP 1995 503cx 60 10M5 Vol. 22 No. 32000 3 carpal tunnel syndrome entrapment neuropathy cm 4 Vol. 22 No. 32000 5 Vol. 22 No. 32000 10 2- microglobulin
268 LSG 図 Lee ABCD 表 1 4 Age BMI C Duration Still DiaRem 表 1 4 HbA1c Ⅱ 対象と方法 1 17 LSG 6 3 Excess Weight Loss EWL BMI 25 kg/m 2 Hb
52 5 18 1 267 原著 ( 臨床研究 ) LSG ABCD DiaRem LSG 3 93.1 1 7.8 CR37.5 PR33.3 1 ABCD 5 DiaRem 12 LSG ABCD DiaRem LSG 腹腔鏡下スリーブ状胃切除術,ABCD スコア,DiaRem スコア Ⅰ はじめに Bariatric Surgery 2 1 metabolic surgery 2 ABCD 2
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
Detection methods of minimal residual disease and their prognostic value in patients with malignant hematological diseases はじめに (m
92 124 3 92 96 2015 Detection methods of minimal residual disease and their prognostic value in patients with malignant hematological diseases はじめに (minimal residual disease: MRD) MRD MRD ( 1) MRD PCR
untitled
2008/04/27 1. 1 2 staticdynamics etc 3 Hedberg A, Carlberg EB, Forssberg H, Hadders-Algra M. Development of postural adjustments in sitting position during the first half year of life. Dev Med Child Neurol.
2001 2003 2005 2006 2007 2008
2001 2003 2005 2006 2007 2008 60 etc. http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm 23.5% 2.8% 2.8% 3.4% 30.3% 9.9% 11.5% 15.8% AAN 65
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Fig.1 Distribution of the cases with bacterial meningitis by age and pathogens Chiba
PTSD 17
- - 3 11 3 18 21 3 11 DMAT 72 3 14 PTSD 17 7 24 2 9 2000 2 3 1 5000 2 3 4 14 200 1 2 DMAT DMAT DMAT 3 4 30 70 13 4 5 6 3 4 6 81 DNA DNA DNA 23 1 2 4 2 3 5 25 4 6 10 4 2 4 1 3 2 1 3 1 3 with you forever
17. (1) 18. (1) 19. (1) 20. (1) 21. (1) (3) 22. (1) (3) 23. (1) (3) (1) (3) 25. (1) (3) 26. (1) 27. (1) (3) 28. (1) 29. (1) 2
1. (1) 2. 2 (1) 4. (1) 5. (1) 6. (1) 7. (1) 8. (1) 9. (1) 10. (1) 11. (1) 12. (1) 13. (1) 14. (1) 15. (1) (3) 16. (1) 1 17. (1) 18. (1) 19. (1) 20. (1) 21. (1) (3) 22. (1) (3) 23. (1) (3) 24. 1 (1) (3)
BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
<8DD AA97A3834C B BF8A69838A C8EA E786C7378>
ST-01738 ErythroClear Red Blood Cell Depletion Reagent kit 臍帯血 2 ml 用 17,000 13,600 ST-01739 ErythroClear Red Blood Cell Depletion kit 臍帯血 2 ml 用 475,000 380,000 ST-07801 Lymphoprep 250 ml 17,000 13,600
取扱説明書 ［F-02F］
F-02F 3. 2 3 4 5 6 7 8 9 0 2 3 4 5 6 7 8 a b c d a b c d 9 a b cd e a b c d e 20 2 22 ab a b 23 24 a c b 25 d e 26 o a b c p q r s t u d h i j k l e f g d m n a b c d e f g h i j k l m n v 27 o P P
PowerPoint Presentation
2 9/ 3 3 9/ 9 4 5 , PR () 6 ,,, (11) 7 PR 8 9 10 11 TEL. 106 8/131512/291/3 TEL. 107 12/291/3 12 http://www.f-turn.jp/ 13 21 4 21 14 200910 U 200911 U 200911 20102 15 20102 PR 20103 20103 16 20103 20104
untitled
,337 37 35 0,349,09 35 55 988 3 0 0 3,387 7 90 0,369,46 5 57 5 0 90 38 8,369 3 4 5 6 7 8 9 0 3 4 5 6 7 8 9 0 3 4 5 6 8 9 30 3 3 5,400 7,00 9,000 0,800,600 4,400 6,00 8,000 9,800,600 3,400 5,00 7,000 8,800